keyword
MENU ▼
Read by QxMD icon Read
search

Urothelial

keyword
https://www.readbyqxmd.com/read/28644132/risk-of-acute-myocardial-infarction-in-upper-tract-urothelial-carcinoma-patients-receiving-radical-nephroureterectomy-a-population-based-cohort-study
#1
Shih-Yi Lin, Cheng-Li Lin, Chao-Hsiang Chang, His-Chin Wu, I-Kuan Wang, Che-Yi Chou, Ji-An Liang
BACKGROUND: The outcomes of upper tract urothelial carcinoma (UTUC) receiving radical nephroureterectomy were usually limited to small sample size, case-control studies, and often focused on cancer progression. Risk of acute myocardial infarction (AMI) in these patients was never investigated. RESULTS: The overall incidences of AMI were 3.39, 1.44, and 1.70 per 10,000 person-years in the radical nephroureterectomy, nonnephroureterectomy, and non-UTUC cohorts, respectively...
June 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28643244/durvalumab-first-global-approval
#2
Yahiya Y Syed
Intravenous durvalumab (Imfinzi™; AstraZeneca) is a fully human monoclonal antibody that blocks programmed cell death ligand-1 binding to its receptors (PD-1 and CD80), resulting in enhanced T-cell responses against cancer cells. The US FDA has granted durvalumab accelerated approval for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy...
June 22, 2017: Drugs
https://www.readbyqxmd.com/read/28642443/squamous-differentiation-in-pt1-bladder-urothelial-carcinoma-predicts-poor-response-for-intravesical-chemotherapy
#3
Gang Li, Jieping Hu, Yuanjie Niu
The role of squamous differentiation in pT1 bladder tumors in the response to intravesical chemotherapy was unknown. We performed a retrospective analysis of 213 pT1 bladder urothelial carcinoma patients with squamous differentiation (group1), the remaining 213 pT1 pure urothelial carcinoma served as controls (group2). All cases were treated with transurethral resection of bladder tumor and subsequent intravesical chemotherapy. Within a five-year period, the tumor recurrence rate was 75.1% (160/213) in group 1 and 64...
June 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/28639914/long-non-coding-rna-urothelial-carcinoma-associated-1-as-a-tumor-biomarker-for-the-diagnosis-of-urinary-bladder-cancer
#4
Zichun Wang, Xiaoxiong Wang, Daming Zhang, Yongchun Yu, Licheng Cai, Cheng Zhang
To investigate the diagnostic value of urothelial carcinoma-associated 1 as a urine biomarker in urinary bladder cancer patients by performing a comprehensive meta-analysis. A comprehensive literature search was conducted by the databases PubMed, Embase, Cochrane Library, China Knowledge Resource Integrated, and Web of Science. The quality of eligible studies was scored with the Quality Assessment of Diagnostic Accuracy Studies. The bivariate meta-analysis model was used to pool the sensitivity, specificity, likelihood ratio, and diagnostic odds ratio...
June 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/28639280/mutational-profiles-of-brenner-tumors-show-distinctive-features-uncoupling-urothelial-carcinomas-and-ovarian-carcinoma-with-transitional-cell-histology
#5
Nicole Pfarr, Silvia Darb-Esfahani, Jonas Leichsenring, Eliane Taube, Melanie Boxberg, Ioana Braicu, Moritz Jesinghaus, Roland Penzel, Volker Endris, Aurelia Noske, Wilko Weichert, Peter Schirmacher, Carsten Denkert, Albrecht Stenzinger
Brenner tumors (BT) are rare ovarian tumors encompassing benign, borderline and malignant variants. While the histopathology of BTs and their clinical course is well described, little is known about the underlying genetic defects. We employed targeted next generation sequencing to analyze the mutational landscape in a cohort of 23 BT cases (17 benign, 2 borderline, 4 malignant) and 3 ovarian carcinomas with transitional cell histology (TCC). Copy number variations (CNV) were validated by fluorescence in-situ hybridization (FISH) and quantitative PCR-based copy number assays...
June 22, 2017: Genes, Chromosomes & Cancer
https://www.readbyqxmd.com/read/28638274/hypoxia-regulated-microrna-210-overexpression-is-associated-with-tumor-development-and-progression-in-upper-tract-urothelial-carcinoma
#6
Hung-Lung Ke, Wei-Ming Li, Hui-Hui Lin, Wei-Chi Hsu, Ya-Ling Hsu, Lin-Li Chang, Chun-Nung Huang, Ching-Chia Li, Hsin-Ping Chang, Hsin-Chih Yeh, Chien-Feng Li, Wen-Jeng Wu
BACKGROUND: Hypoxia has been shown to facilitate tumor progression. Hypoxia-regulated microRNA-210 (miR-210) may play an important role in carcinogenesis and tumor progression. In this study, we evaluated the clinical significance of miR-210 expression in upper tract urothelial carcinoma (UTUC). METHODS: Eighty-three UTUC patients participated in this study. All of them provided cancer tissue samples and 50 of them provided non-cancerous urothelium samples. Clinicopathologic data were collected by reviewing medical records...
2017: International Journal of Medical Sciences
https://www.readbyqxmd.com/read/28638271/proex-c-as-diagnostic-marker-for-detection-of-urothelial-carcinoma-in-urinary-samples-a-review
#7
REVIEW
Gerardo Botti, Maria Gabriella Malzone, Elvira La Mantia, Micaela Montanari, Daniela Vanacore, Sabrina Rossetti, Vincenzo Quagliariello, Carla Cavaliere, Rossella Di Franco, Luigi Castaldo, Gianluca Ametrano, Francesca Cappuccio, Francesco Jacopo Romano, Raffaele Piscitelli, Maria Filomena Pepe, Carmine D'Aniello, Gaetano Facchini
The gold standard for the detection of urothelial carcinoma is represented by urethro-cystoscopy and biopsy. Both procedures are invasive and expensive and therefore cytology is often used as first approach to investigate on a possible neoplasia, being a safe and cost-effective diagnostic modality of evaluation. Because cytology alone is not highly sensitive for detection of low grade urothelial carcinoma and recurrence of the disease, several adjunct markers and urine based tests for urothelial carcinoma have been developed, which can help in the final diagnosis...
2017: International Journal of Medical Sciences
https://www.readbyqxmd.com/read/28636553/the-prognostic-and-diagnostic-value-of-circulating-tumor-cells-in-bladder-cancer-and-upper-tract-urothelial-carcinoma-a-meta-analysis-of-30-published-studies
#8
Zheng Zhang, Wei Fan, Qiaoling Deng, Shihui Tang, Ping Wang, Peipei Xu, June Wang, Mingxia Yu
There are inconsistent conclusions in the association between circulating tumor cells (CTCs) and urothelial cancer (UC). We performed a meta-analysis to assess the prognostic and diagnostic value of CTCs in UC. We search Medline, Embase and Web of science for relevant studies. The study was set up according to the inclusion/exclusion criteria. 30 published studies with a total of 2161 urothelial cancer patients were included. Meta-analysis showed that CTC-positive was significantly associated with tumor stage (≤ II vs III, IV) (OR = 4...
June 16, 2017: Oncotarget
https://www.readbyqxmd.com/read/28634245/targeting-nectin-4-in-bladder-cancer
#9
(no author information available yet)
Preliminary findings from a phase I clinical trial indicate that enfortumab vedotin, an investigational antibody-drug conjugate targeting nectin-4, shows considerable efficacy in metastatic urothelial carcinoma. Robust responses were seen even among patients with disease progression on platinum chemotherapy and/or immune checkpoint blockade.
June 20, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28634017/the-over-time-conditional-survival-of-intravesical-recurrence-in-upper-tract-urothelial-carcinoma
#10
Keisuke Shigeta, Eiji Kikuchi, Masayuki Hagiwara, Toshiyuki Ando, Ryuichi Mizuno, Takayuki Abe, Shuji Mikami, Akira Miyajima, Ken Nakagawa, Mototsugu Oya
PURPOSE: Since a conditional survival (CS) analysis provides better estimates of survival times at each follow-up, we aimed to assess changes in conditional intravesical recurrence-free survival (IVRFS) rates after radical nephroureterectomy (RNU) and how the impact of well-known risk factors evolves over time, particularly in localized upper tract urothelial carcinoma (UTUC) patients. MATERIALS AND METHODS: We identified 364 patients with Ta-3N0M0 UTUC who underwent open or laparoscopic RNU at our three institutions...
June 17, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28633756/immunotherapy-the-wave-of-the-future-in-bladder-cancer
#11
Daniel P Petrylak
Urothelial cell carcinoma (UC) is one of the most common cancers and one of the most deadly. Metastatic UC is particularly hard to treat, because it is typically diagnosed when patients are elderly and have medical comorbidities. Many patients with metastatic UC are unable to receive cisplatin-based chemotherapy, due to older age at diagnosis and comorbidities, and even when platinum chemotherapy can be administered, it has limited success in prolonging survival. Recently, improved understanding of molecular targets and immunologic characteristics of urothelial tumor cells has resulted in new therapeutic approaches that may help optimize first- and second-line therapy...
June 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28633191/-urothelial-cancer-update-on-systemic-treatment-options
#12
Günter Niegisch
Perioperative chemotherapy is likely to improve survival in both the neoadjuvant and the adjuvant setting. Therefore, it is an integral part of the modern treatment of patients with muscle-invasive urothelial bladder cancer. All patients who are suitable for cisplatin-based chemotherapy should be involved in a corresponding concept.Cisplatin-based combinations are standard regimens in the perioperative and palliative systemic treatment of urothelial cancer. Carboplatin is only an inferior substitute for "unfit" patients in the palliative treatment situation...
June 20, 2017: Aktuelle Urologie
https://www.readbyqxmd.com/read/28632777/immunohistochemiocal-subtyping-using-ck20-and-ck5-can-identify-urothelial-carcinomas-of-the-upper-urinary-tract-with-a-poor-prognosis
#13
Danijel Sikic, Bastian Keck, Sven Wach, Helge Taubert, Bernd Wullich, Peter J Goebell, Andreas Kahlmeyer, Peter Olbert, Philipp Isfort, Wilhelm Nimphius, Arndt Hartmann, Johannes Giedl
PURPOSE: Genome-wide analyses revealed basal and luminal subtypes of urothelial carcinomas of the bladder. It is unknown if this subtyping can also be applied to upper tract urothelial carcinomas. MATERIALS AND METHODS: Tumor samples from 222 patients with upper tract urothelial carcinomas who were treated with radical nephroureterectomy were analyzed for the expression of seven basal/luminal immunohistochemical markers (CK5, EGFR, CD44, CK20, p63, GATA3, FOXA1)...
2017: PloS One
https://www.readbyqxmd.com/read/28631918/-using-of-cell-biocomposite-material-in-tissue-engineering-of-the-urinary-bladder
#14
P V Glybochko, Yu V Olefir, Yu G Alyaev, D V Butnaru, E A Bezrukov, A A Chaplenko, T M Zharikova
In a systematic review, to present an overview of the current situation in the field of tissue engineering of urinary bladder related to the use of cell lines pre-cultured on matrices. The selection of eligible publications was conducted according to the method described in the article Glybochko P.V. et al. "Tissue engineering of urinary bladder using acellular matrix." At the final stage, studies investigating the application of matrices with human and animal cell lines were analyzed. Contemporary approaches to using cell-based tissue engineering of the bladder were analyzed, including the formation of 3D structures from several types of cells, cell layers and genetic modification of injected cells...
June 2017: Urologii︠a︡
https://www.readbyqxmd.com/read/28629334/protein-kinase-c-%C3%AE-pkc%C3%AE-modulates-cell-apoptosis-by-stimulating-nuclear-translocation-of-nf-kappa-b-p65-in-urothelial-cell-carcinoma-of-the-bladder
#15
Jin Zheng, Chuize Kong, Xiaoxi Yang, Xiaolu Cui, Xuyong Lin, Zhe Zhang
BACKGROUND: The protein kinase C (PKC) family comprises central regulators of multiple signal transduction processes and is involved in the progression of many cancers. Nuclear factor Kappa-B (NF-κB) is constitutively expressed in cancer tissues and stimulates the transcription of various tumor-related genes. The present study aims to investigate the clinical significance of PKCα and NF-κB p65 in bladder cancer tissues and the mechanism underlying PKCα induction of bladder cancer cell apoptotic resistance through stimulation of p65 nuclear translocation...
June 19, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28628011/-criteria-for-selection-of-tumor-cells-and-prospects-for-specific-immunotherapy-for-bladder-cancer
#16
T Slavyanskaya, S -Salnikova, R Sepiashvili
Specific antitumor immunotherapy with autologous dendritic cell vaccines is one of the new approaches of modern medicine. For activation of dendritic cells highly immunogenic antigens are used, however optimal antigens in case of bladder cancer (BC) are still not researched. Cancer-testis antigens (CTA) are the most promising target in the context of creation of antitumor vaccines, because they are distinguished by pronounced immunogenicity, they are detected in different types of tumors and have limited pattern of expression in healthy tissues of grown-up organism...
May 2017: Georgian Medical News
https://www.readbyqxmd.com/read/28628010/-the-main-stages-of-the-preparation-of-viable-tumor-cells-of-bladder-cancer-from-isolation-of-the-tumor-material-till-cryopreservation-of-cell-lines
#17
T Slavyanskaya, S -Salnikova
The development of personalized autologous dendritic cell anti-tumor vaccines (PDPW) against bladder cancer (BC) is a relevant issue that covers many aspects required for its standardization. The article presents personal experimental studies related to development of optimal conditions of transportation of biological material; temperature and temporary modes for the storage of the samples; the materials about the optimal method of disaggregation of the biomaterial; there has been shown a comparative analysis of different methods of tumor disaggregation; the selection of nutritious growth mediums and growth factors for urothelial carcinoma cells (UCC), the conditions of cryopreservation of tumor cells for maximum UCC viability, potentially suitable for creating PDPW against BC...
May 2017: Georgian Medical News
https://www.readbyqxmd.com/read/28627636/formulation-and-characterization-of-egcg-for-the-treatment-of-superficial-bladder-cancer
#18
Katarzyna Dettlaff, Maciej Stawny, Magdalena Ogrodowczyk, Anna Jelińska, Waldemar Bednarski, Dorota Wątróbska-Świetlikowska, Rick W Keck, Omar A Khan, Ibrahim H Mostafa, Jerzy Jankun
In the United States, the annual incidence of bladder cancer is approximately 70,000 new cases, with a mortality rate of approximately 15,000/year. The most common subtype (70%) of bladder cancer is superficial, namely hte non-muscle invasive disease form limited to the urothelium. The rate of progression and recurrence is up to 40 and 70%, respectively. Urothelial cell carcinoma of the bladder is typically treated with transurethral resection. The cancerous cells can float onto the adjacent epithelium, increasing the risk of recurrence...
June 14, 2017: International Journal of Molecular Medicine
https://www.readbyqxmd.com/read/28626955/expression-profile-of-urothelial-transcription-factors-in-bladder-biopsies-with-interstitial-cystitis
#19
Kanya Kaga, Ken-Ichi Inoue, Mayuko Kaga, Tomohiko Ichikawa, Tomonori Yamanishi
OBJECTIVES: To characterize interstitial cystitis pathology based on the expression profile of urothelial tissue-specific master transcription factors. METHODS: Bladder carcinoma cell lines derived from the urothelial stem cells (epithelial or mesenchymal) were used to identify candidate urothelial master transcription factors. Gene expression was measured with quantitative reverse transcription polymerase chain reaction. From the initial screening of 170 transcription factors (human homologs of Drosophila segmentation genes and known master transcription factors from a database), 28 transcription factors were selected...
June 18, 2017: International Journal of Urology: Official Journal of the Japanese Urological Association
https://www.readbyqxmd.com/read/28625477/challenges-and-advances-in-the-diagnosis-biology-and-treatment-of-urothelial-upper-tract-and-bladder-carcinomas
#20
REVIEW
Jeanny B Aragon-Ching
Urothelial carcinomas span the bladder, ureter, and renal pelvis, and while there had been stagnation in the field of drug approval for the past two decades, there is now accelerated and regular US FDA approval of 5 immunotherapy agents. However, patients who inherently do not respond or progress on such therapies still represent an area of increased unmet need. In this special Seminars issue, we explore varying aspects of bladder urothelial carcinoma treatment with targeted therapies, the unique presentation and challenges in the treatment of upper tract and renal pelvis tumors, as well as new and emerging diagnostic imaging tools for varying genitourinary cancers...
July 2017: Urologic Oncology
keyword
keyword
4084
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"